Varinder Singh has joined AbbVie as Business Unit Director – Oncology, bringing with him over two decades of rich experience in the pharmaceutical and healthcare industry. In his new role, Varinder will lead AbbVie’s oncology business in India, driving strategic initiatives, market growth, and patient-focused innovations in cancer care.
Before joining AbbVie, Varinder was associated with Cipla for more than seven years, most recently serving as Business Head – Oncology. He led three high-performing teams across sales and marketing, managing a robust oncology portfolio and delivering strong business results. His leadership was instrumental in launching new therapies, driving commercial excellence, and strengthening Cipla’s position in the oncology segment.
Varinder’s professional journey spans several leading global pharmaceutical companies, including Roche, Eisai, AstraZeneca, Sanofi Genzyme, and Ranbaxy. At Roche, he managed oncology operations across West and East India, overseeing a portfolio exceeding ₹100 crore. At Eisai, he successfully launched the company’s oncology division in Western India, setting a strong foundation for its future growth. His experience across diverse roles has equipped him with deep expertise in brand launches, strategic planning, and cross-functional leadership.
With his extensive background in oncology and a track record of building high-performing teams, Varinder is poised to steer AbbVie’s oncology business toward sustained growth and innovation. His appointment underscores AbbVie’s commitment to strengthening its leadership in oncology and delivering advanced, life-changing therapies to patients in India.